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MaBACKGROUND Isolated tricuspid valve surgery is associatedwith highmorbidity andmortality, especially in patientswith
prior cardiac surgery. The transcatheter Forma Repair System (Edwards Lifesciences, Irvine, California) is designed to pro-
vide a surface for native leaﬂet coaptation to reduce tricuspid regurgitation (TR) by occupying the regurgitant oriﬁce area.
OBJECTIVES This study sought to evaluate the feasibility and exploratory efﬁcacy with this transcatheter repair system
for the treatment of severe TR.
METHODS Seven high-risk patients with severe TR and clinical signs of heart failure were declined for surgery and
offered transcatheter treatment with this device. All procedures were performed within a cardiac catheterization labo-
ratory or hybrid operating room under general anesthesia with transesophageal echocardiographic guidance. Vascular
access was via the left axillary vein. Baseline characteristics, procedural and in-hospital outcomes, as well as 30-day
follow-up were prospectively collected.
RESULTS All patients had severe TR and New York Heart Association (NYHA) functional class II to IV (mean age 76  13
years; mean logistic EuroSCORE 25.7  17.4%), and underwent device implantation to improve tricuspid leaﬂet coap-
tation, thereby reducing TR. Device implantation was successful without procedural complications in all patients, with
signiﬁcant reductions in TR severity (moderate in 3 patients and mild in 4 patients). Median hospital length of stay was 4
days. At 30-day follow-up, all patients but 1 demonstrated improvements in NYHA functional status (to class II) with
pronounced reductions in the presence and severity of peripheral edema. TR severity was assessed as being moderate at
30-day transthoracic echocardiography follow-up in all patients. No complications related to the device or vascular
access were observed during follow-up.
CONCLUSIONS A transcatheter-based treatment option for severe TR appears safe and feasible with this repair sys-
tem. Improvements in TR severity were documented in all patients, which were accompanied by improvements in pe-
ripheral edema and functional status. (J Am Coll Cardiol 2015;66:2475–83) © 2015 by the American College of
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ABBR EV I A T I ON S
AND ACRONYMS
6MWT = 6-min walk test
AF = atrial ﬁbrillation
CT = computed tomography
LVS = left-sided valve surgery
NYHA = New York Heart
Association
RV = right ventricle/ventricular
TEE = transesophageal
echocardiography
TR = tricuspid regurgitation
TTE = transthoracic
echocardiography
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2476D espite its association with poor sur-vival, severe tricuspid regurgita-tion (TR) is an under-recognized
and undertreated condition; its clinical con-
sequences being independent of age, left
ventricular ejection fraction, or pulmonary
artery pressures (1). Moderate-to-severe TR
is present in 1.6 million U.S. individuals,
yet <0.5% of this population underwent sur-
gical tricuspid repair or replacement (2). In
patients undergoing left-sided valve surgery
(LVS), concomitant tricuspid valve repair is
universally recommended in the presence of
severe coexistent TR (3,4). Moreover, the
role of surgical intervention for symptomaticsevere TR late following LVS remains unclear. Iso-
lated tricuspid valve surgery is associated with signif-
icant in-hospital mortality and poor long-term
survival, especially in patients with prior mitral or
aortic valve surgery (5,6).SEE PAGE 2484In this regard, alternative minimally invasive
surgical and percutaneous transcatheter treatment
alternatives were recently developed in an attempt to
improve the prognosis and quality of life of patients
with severe TR. Novel treatment options include
percutaneous annular rings, transcatheter suture
bicuspidization, valved stents, or heterotopic place-
ment of transcatheter aortic valves in the vena cava
(7–9). The Forma Repair System (Edwards Life-
sciences, Irvine, California) is a novel transcatheter
treatment alternative for patients with severe TR and
prohibitive operative risk. The device is designed to
reduce severe TR by occupying the regurgitant oriﬁce
area and providing a surface for native leaﬂet coap-
tation. Herein we describe the ﬁrst-in-man device
experience with this novel therapeutic concept,
focusing on the safety, feasibility, and preliminary
efﬁcacy in reducing severe TR and right heart failure
at 30-day follow-up.
METHODS
PATIENT SCREENING. Patients with severe TR and
symptoms of heart failure, deemed to be at high
surgical risk, were considered suitable candidates for
this novel device. Only patients with functional TR
and without pacemaker/implantable cardioverter-
deﬁbrillator leads or prior tricuspid surgery were
considered. Following careful evaluation by a heart
team, surgical tricuspid valve repair or replacement
was deemed to be associated with an unacceptable
surgical risk. All procedures were approved by HealthCanada under a Special Access program, and all pa-
tients provided signed informed consent for the
procedures.
TR severity was assessed by transthoracic echo-
cardiography (TTE) in all patients. In some patients,
transesophageal echocardiography (TEE) assisted in
establishing the mechanism of regurgitation and the
presence of multiple jets. TR severity was graded as
mild, moderate, or severe. The severity of TR was
determined on the basis of the color ﬂow TR jet (large
central and holosystolic jet with systolic ﬂow reversal
on hepatic veins) and the vena contracta width
($7 mm) (10). Cardiac computed tomography (CT)
was also used to measure tricuspid annular di-
mensions, RV diameters, and the distance from the
valvular annulus to the RV apex. Finally, subclavian
and axillary left veins were assessed by CT to ensure
their size was compatible with the introducer sheath
and the device.
DEVICE CONCEPT. This transcatheter repair system
is designed to reduce TR by occupying the regurgitant
oriﬁce area and providing a surface for native leaﬂets
coaptation (Figure 1, Central Illustration). The device
consists of a spacer and a rail that is anchored at the
RV apex. The spacer is a foam-ﬁlled polymer balloon
that passively expands via holes in the spacer shaft.
Two radiopaque markers help to initially position the
spacer using ﬂuoroscopy. There are 2 spacer sizes
currently available (12 mm and 15 mm), with a length
of 42 mm. The device is ﬁxed at the distal end in the
RV myocardium. The ﬁxation mechanism consists of
a 6-pronged nitinol anchor that is designed to mini-
mize both the risk of penetration of the epicardial
surface and the prong exposure in the RV.
PROCEDURE. Procedures were undertaken within a
cardiac catheterization laboratory or hybrid operating
room using general anesthesia. During all stages of
device implantation, ﬂuoroscopic guidance coupled
with 2-dimensional or 3-dimensional TEE was uti-
lized to ensure optimal device positioning. Following
left axillary vein access, a 24-F sheath was secured in
place to accommodate the largest spacer size (15 mm).
Right ventriculography was performed to locate the
tricuspid annular plane and RV apex (Figure 2A). An
ideal target location is identiﬁed to allow the device
to be perpendicular to the valve plane as well as to
allow all leaﬂets to coapt with the device. The anchor
site is aimed at the RV wall perpendicular to the
center of the annulus (red asterisk, Figure 2A). A
steerable delivery catheter is positioned within the
RV to deliver the rail system to the ideal location
(Figure 2B). The spacer is then tracked over the rail to
the tricuspid valve plane and placed in the best
position to reduce TR, assessed live with TEE
FIGURE 1 The Forma Repair System
(A) Spacer. (B) Steerable delivery catheter and anchoring system. (C) Device at the tricuspid valve annulus, anchoring system at the right
ventricular apex, and excess device length coiled into a subcutaneous pocket.
CENTRAL ILLUSTRATION Novel Transcatheter Repair System for
Severe Tricuspid Regurgitation: Exercise Capacity and Quality of Life
Before and After Device Implantation
Campelo-Parada, F. et al. J Am Coll Cardiol. 2015; 66(22):2475–83.
(Top) Six-min walk test (6MWT) and Kansas City Cardiomyopathy Questionnaire of quality
of life (KCCQ) results before device implantation and at 30-day follow-up (FU) in 5 and 4
patients, respectively. (Bottom) The Forma device showing the anchor system at right
ventricular apex and the spacer at the tricuspid valve annulus.
J A C C V O L . 6 6 , N O . 2 2 , 2 0 1 5 Campelo-Parada et al.
D E C E M B E R 8 , 2 0 1 5 : 2 4 7 5 – 8 3 Transcatheter Treatment of TR
2477(Figure 2C and 2D). The device is then locked proxi-
mally, and the excess rail length is coiled and placed
within a subcutaneous pocket (Figure 3). The entire
device is fully retrievable during all stages of the
procedure, if needed, until sheath removal.
POST-PROCEDURE AND FOLLOW-UP. Post-procedure,
patients were admitted to a cardiology ward for
clinical observation. A post-procedure TTE veriﬁed
appropriate device positioning. Rail system integrity
and position were also conﬁrmed with cardiac CT
and/or chest x-ray. First post-procedural follow-up
was scheduled at 30 days along with TTE, chest x-ray,
blood tests, and clinical examination. Baseline char-
acteristics of all patients, procedural and hospital
outcomes, as well as results of follow-up were pro-
spectively collected. This is a descriptive study, and
no statistical analyses were performed.
RESULTS
BASELINE CHARACTERISTICS. A total of 11 patients
were considered potential candidates for device im-
plantation. Of these, 4 patients were excluded due to
the following reasons: decision of surgical tricuspid
replacement (n ¼ 1), concomitant gastric cancer with
limited expected survival (n ¼ 1), extremely dilated
RV and tricuspid annulus with very large coaptation
defect (n ¼ 1), and previous chest radiotherapy lead-
ing to a lack of sufﬁcient subcutaneous and muscular
tissue to accommodate the pocket where the excess
rail length of the device system is placed (n ¼ 1). A
total of 7 patients were ﬁnally enrolled in this initial
experience with the device, and their baseline clinical
characteristics are described in Table 1. Mean age was
76  13 years, and the mean logistic EuroSCORE was
FIGURE 2 Intraprocedural Fluoroscopic/Angiographic Images
(A) Right ventriculography to locate the tricuspid annular plane and identify the ideal anchor location (red asterisk) on ﬂuoroscopy. (B) Right
ventricular anchoring via a steerable delivery catheter. (C) Device positioning in the valve plane. (D) Final right ventriculography with the device
in correct position (red arrow) and reduction of tricuspid regurgitation from baseline.
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247825.7  17.4%. All patients at baseline presented with a
normal left ejection fraction (56  5%) and New York
Heart Association (NYHA) functional class III or IV
(n ¼ 6, 1 patient was in class II). Pulmonary hyper-
tension was observed in 5 patients, and 5 patients had
prior cardiac surgery (prior coronary artery bypass
grafting in all with aortic or mitral valve surgery in 4
of them). Permanent atrial ﬁbrillation (AF) was pre-
sent in 5 patients, and 6 patients had renal insufﬁ-
ciency, 1 of whom was dialysis-dependent. The mean
baseline daily furosemide dose was 80  61 mg. All
patients had baseline concomitant mild or mild-to-
moderate mitral regurgitation. Tricuspid valve vena
contracta was measured in the 2- and 4-chamber
views on TTE. Mean maximal vena contracta in this
group of patients measured 15.5  5.1 mm; a conse-
quence of leaﬂet noncoaptation with resultant se-
vere, symptomatic TR.PROCEDURAL, IN-HOSPITAL, AND 30-DAY RESULTS.
Table 2 summarizes procedural results and in-hospital
outcomes. All patients underwent successful device
implantation without procedural complications. One
12-mm device was retrieved and replaced for the
largest 15-mm device during the same procedure to
achieve a better result. The degree of TR was reduced
intraprocedurally by at least 1 degree in all patients,
and 4 patients had a reduction of 2 degrees (up to mild
TR). New-onset AF appeared in 1 of the 2 patients
without AF at baseline. One patient experienced
several episodes of asymptomatic nonsustained ven-
tricular tachycardia during the 24 h following the
procedure, originating from the right ventricle (RV)
and subsequently controlled with beta-blockers. In 2
other patients, frequent premature ventricular con-
tractions (couplets or triplets) were seen during the
ﬁrst day post-intervention. One patient experienced
FIGURE 3 X-Ray Images of the Device After Implantation
(A) Chest x-ray after device implantation. (B) Image detail showing the 2 radiopaque
markers of the coaptation system and the anchor (black arrow) at the right ventricle.
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2479minor bleeding related to vascular access. The same
patient had a more prolonged hospitalization due to
pneumonia and renal failure. The median hospital
length of stay was 4 (3 to 6) days. All patients but 1
received vitamin K antagonists as antithrombotic
therapy following the procedure.
Tables 3 and 4 describe outcomes at 30-days post-
procedure. All patients were alive and completed
the 30-day follow-up. No additional complications
occurred between hospital discharge and 30-day
follow-up. All patients but 1 demonstrated improve-
ment in their NYHA functional status to class II (the
patient in class II at baseline had no change in the
functional class at follow-up) coupled with signiﬁcant
reduction in peripheral edema. Diuretic dosage was
reduced in 2 patients at ﬁrst clinical follow-up. No
other signiﬁcant changes in patients’ medication
were noted. TR was assessed as being moderate in
severity at the 30-day TTE in all patients, and there
was no apparent iatrogenic tricuspid stenosis result-
ing from the device (Figure 4). A total of 4 and 5
patients had quality of life (Kansas City Cardiomy-
opathy Questionnaire) and exercise capacity (6-min
walk test [6MWT]) evaluation at baseline and at
30-day follow-up, respectively. Quality of life im-
proved in all of these 4 patients (from 59.6  14.1 to
86.2  5.4), and exercise capacity improved in 4 of
5 patients (mean 6MWT distance from 297  66 m to
326  74 m) (Central Illustration). One patient failed to
complete the total 6-min duration due to arthritic
joint pain (although at 5 min, the distance covered
was greater than pre-device insertion). No ongoing
device or vascular access-related complications or
infection were documented at 30-day follow-up.
DISCUSSION
This repair system is a novel transcatheter treatment
option for signiﬁcant TR. In this seminal series of 7
patients who were at high or prohibitive risk for sur-
gery, all underwent successful device implantation
without major procedural complications. All patients
demonstrated improvements in TR severity, periph-
eral edema, and functional status. Furthermore, no
signiﬁcant access site or device-related complications
were seen at 30-days post-procedure.
TR is not a benign condition, with a step-wise rela-
tionship between TR severity and mortality rates (11).
In patients undergoing mitral valve surgery, concom-
itant and untreated moderate or severe TR is associ-
ated with lower mid-term survival rates (12). In a large
series published by Nath et al. (1), 1-year survival was
63.9% in those with severe TR, independent of age,
biventricular systolic function, RV size, and the degreeof inferior vena cava dilation. Despite this knowledge,
isolated tricuspid valve repair or replacement seldom
occurs, invariably occurring concomitantly at the time
of LVS (13). Current European and American Heart
Association/American College of Cardiology guide-
lines on valvular heart disease recommend concurrent
tricuspid valve repair at the time of LVS if the tricuspid
valve annulus is dilated, even if TR is found not to be
severe (3,4). This more aggressive criterion is aimed to
avoid ongoing signiﬁcant TR progression during
follow-up (14,15). Isolated tricuspid valve surgery late
following initial LVS is associated with poor clinical
outcomes including in-hospital mortality rates
approaching 10% (5,13). However, other studies re-
ported better outcomes using less invasive access via a
right lateral thoracotomy (16). As such, there is an
ongoing unmet clinical need for less-invasive yet
effective treatment options for patients with signiﬁ-
cant TR left surgically untreated.
TABLE 1 Baseline Clinical and Echocardiographic Characteristics
(N ¼ 7)
Age, yrs 76  13
Male 4 (57)
NYHA functional class $III 6 (86)
Coronary artery disease 6 (86)
Prior open heart surgery 5 (71)
Prior valve surgery 4 (57)
Mitral 2 (29)
Aortic 2 (29)
COPD 1 (14)
Permanent atrial ﬁbrillation 5 (71)
Pulmonary hypertension 5 (71)
Creatinine clearance <60 ml/min (eGFR) 6 (86)
Hemodialysis 1 (14)
Logistic EuroSCORE, % 25.7  17.4
6-Min walk test, m 297  66
Kansas City Cardiomyopathy Questionnaire 59.6  14.1
Daily furosemide dose, mg 80  61
Baseline echocardiogram
LVEF, % 56  5
PAPs, mm Hg 69.7  6.0
MR grade
Mild 3 (43)
Mild to moderate 3 (43)
Moderate 1 (14)
Severe TR grade 7 (100)
Vena contracta, mm 15.5  5.1
TAPSE, mm 16.5  4.2
TAPSV, cm/s 10.6  2.0
RV diameter, mm 47  7
Baseline CT data
Tricuspid valve major diameter, mm 50.3  6.0
Tricuspid valve minor diameter, mm 43.2  2.0
Values are mean  SD or n (%).
COPD ¼ chronic obstructive pulmonary disease; CT ¼ computed tomography;
eGFR ¼ estimated glomerular ﬁltration rate; LVEF ¼ left ventricular ejection
fraction; MR ¼ mitral regurgitation; NYHA ¼ New York Heart Association; PAPs ¼
systolic pulmonary artery pressure; RV¼ right ventricle; TAPSE ¼ tricuspid annular
plane systolic excursion; TAPSV ¼ tricuspid annular peak velocity; TR ¼ tricuspid
regurgitation.
TABLE 2 Post-Procedural and In-Hospital Outcomes (N ¼ 7)
Procedural results
Successful device implantation 7 (100)
Conversion to open heart surgery 0 (0)
Device retrieval 1 (14)
Cardiac tamponade 0 (0)
Access site complication 1 (14)
Procedural time, skin to skin, min 122  34
Contrast volume, ml 71  32
Venous closure
Surgical suture 5 (71)
Percutaneous* 2 (29)
Intraprocedural TEE TR reduction >1 grade 7 (100)
Hospital outcomes
Renal failure 1 (14)
Conduction disturbance/arrhythmia 2 (29)
Bleeding (VARC-2 criteria)
Minor 1 (14)
Major 0 (0)
Vascular or access site complication
Minor 1 (14)
Major 0 (0)
Pneumonia 1 (14)
Pulmonary embolism 0 (0)
Hospitalization length, days 4 (3–6)
In-hospital mortality 0 (0)
Values are n (%), mean  SD, or median (interquartile range). *With the Perclose
Proglide closure system (Abbott Vascular, Santa Clara, California).
TEE ¼ transesophageal echocardiography; TR ¼ tricuspid regurgitation;
VARC-2 ¼ Valve Academic Research Consortium-2.
TABLE 3 30-Day Follow-Up Outcomes (N ¼ 7)
Death 0 (0)
NYHA functional class
I 0 (0)
II 7 (100)
>III 0 (0)
Peripheral edema reduction 7 (100)
Furosemide dose reduction from baseline 2 (29)
Access site complication 0 (0)
6-min walk test, m 326  74
Kansas City Cardiomyopathy Questionnaire 86.2  5.4
Re-hospitalization 0 (0)
Echocardiography data
LVEF, % 57  4
TR grade
Mild 0 (0)
Moderate 7 (100)
Severe 0 (0)
Trans-tricuspid gradient, mm Hg 1.2  0.3
TAPSE, mm 18.5  5.3
TAPSV, cm/s 10.2  2.4
RV diameter 46  8
Values are n (%) or mean  SD.
Abbreviations as in Table 1.
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2480During recent years, and following the success of
other percutaneous devices for treating structural
heart disease, there is a growing interest in novel
treatment paradigms for this often neglected valve
lesion. Percutaneous treatment options represent an
important alternative in patients deemed at high
surgical risk who are refractory to medical therapy
alone. However, there is currently a paucity of data
relating to the feasibility, safety, and results of
various percutaneous tricuspid devices. A percuta-
neous bicuspidization of the tricuspid valve was
achieved using the Mitralign system (Tewksbury,
Massachusetts). This transcatheter device, based
upon pledgeted sutures and designed to plicate
the mitral annulus, was successfully implanted in a
patient with severe TR (7). The TriCinch System
TABLE 4 Individual Changes in TR Severity, RV Function, Exercise Capacity, and Quality of Life
Patient #
TR Degree
(Baseline, TTE)
TAPSE
(mm, Baseline)
RV Diameter
(mm, Baseline)
KCCQ
(Baseline)
6MWT
(Baseline)
TR Degree
(Procedural, TEE)
TR Degree
(30 Days, TTE)
TAPSE
(mm, 30 Days)
RV Diameter
(mm, 30 Days)
KCCQ
(30 Days)
6MWT
(m, 30 Days)
1 Severe 14 57 62.02 261 Mild Moderate 10 55 82.85 293
2 Severe NA 41 NA NA Mild Moderate NA 50 NA NA
3 Severe NA 43 NA NA Mild Moderate 15 36 NA NA
4 Severe 21 40.5 45.95 250 Moderate Moderate 18 39.8 87.1 240*
5 Severe 12 40 52.21 237 Moderate Moderate 24 40 81.38 298
6 Severe 19 50 78.38 385 Moderate Moderate 21 44.7 93.48 430
7 Severe NA 51 NA 350 Mild Moderate 23 48 NA 370
*Test stopped at 5 min due to arthritic joint pain.
6MWT ¼ 6-min walk test; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; other abbreviations as in Tables 1 and 2.
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2481(4Tech, Dublin, Ireland) is currently being evaluated
in a Phase 1 trial. It achieves a tricuspid annular
reduction via a transfemoral approach by applying
tension with a Dacron band anchored at the tricuspid
annulus and inferior vena cava (17). Transcatheter
tricuspid valve implantation in native valves has thus
far only been reported in animal models using
custom-made valves (18–20). In patients with degen-
erated tricuspid bioprostheses or failed surgical
annuloplasty rings, the presence of this rigid struc-
ture allows safe valve implantation with a trans-
catheter aortic or pulmonic valve (21,22). The
implantation of valves at the inferior cavoatrial
junction or both superior and inferior vena cava was
also reported with satisfactory hemodynamic out-
comes, initially with a custom-made self-expandable
valve and later with a Sapien XT valve (EdwardsFIGURE 4 Echocardiography Images Before and After Device Implan
Apical 4-chamber view of transthoracic echocardiography of the same pLifesciences, Irvine, California), with associated pos-
itive RV remodeling noted in the ﬁrst group of pa-
tients (8,9,23). A transatrial intrapericardial tricuspid
annuloplasty device, consisting of a circumferential
device deployedwithin the pericardial space tomodify
tricuspid annular dimensions and reduce functional
TR, was reported in an animal model (24). Another
device under pre-clinical development (Millipede,
Ann Arbor, Michigan) is a tricuspid annuloplasty ring
that can be attached percutaneously or via minimally
invasive surgery (25).
A key differential design feature of this trans-
catheter repair system is the presence of a spacer. The
initial experience with this device demonstrated no
major safety issues coupled with a high rate of suc-
cessful implantation. When evaluating the efﬁcacy of
the device in reducing TR severity, the presence oftation
atient before (left) and after the device implantation (right).
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients with severe,
symptomatic secondary TR at high surgical risk,
transcatheter reduction therapy can be performed
with a low short-term risk of complications and may
represent an acceptable alternative strategy.
TRANSLATIONAL OUTLOOK: Further studies are
necessary to establish the long-term efﬁcacy of
transcatheter interventions to improve right heart
failure, functional status, and quality of life in patients
with severe secondary TR.
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2482the spacer between the valve leaﬂets makes it difﬁcult
to accurately assess TR severity post-device implan-
tation, because vena contracta size and effective
regurgitant oriﬁce areas are difﬁcult to quantify.
Consequently, only a qualitative analysis of color
Doppler ﬂow was possible to evaluate post-procedural
results. At 30-days post-procedure, all patients
demonstrated TR assessed as moderate in severity.
One possible explanation for the small degree
(1 degree) of TR reduction measured qualitatively with
TTE possibly relates to the large mean baseline vena
contracta size in our cohort. The mean vena contracta
size was of similar magnitude to the largest-sized
spacer currently available (15 mm). Despite good de-
vice positioning, complete coaptation was, however,
not achieved, resulting in a signiﬁcant residual degree
of post-procedural TR. Also, the very advanced stage of
the disease in most patients may have played a role in
the mild reduction in TR at 30 days. Nevertheless, we
observed that a reduction from severe to moderate TR
seemed sufﬁcient to impart signiﬁcant reductions in
signs of right heart failure as well as improving
functional status in all patients. As such, larger studies
will need to be undertaken to further test the
safety and efﬁcacy of this novel device. Speciﬁc
criteria for quantifying RV dysfunction and pulmonary
hypertension, along with novel quantitative echocar-
diographic imaging criteria, may be required for opti-
mizing patient selection for transcatheter tricuspid
devices such as the Forma device. It is conceivable that
larger than currently available spacer sizes may be
required to improve echocardiographic results in pa-
tients with large noncoaptation defects and vena
contracta. Some increase in the severity of TR was
observed in 4 patients 30 days after the procedure.
Whereas this may be related to the use of procedural
TEE under general anesthesia versus TTE without
anesthesia at 30 days, follow-up imaging studies are
mandatory to determine the long-term beneﬁcial
effects of the device.
STUDY LIMITATIONS. The evaluation of baseline and
30-day exercise (6MWT) capacity and quality-of-life
examinations were not systematically performed in allpatients. Echocardiography data was not evaluated in
a centralized echocardiography core laboratory. No
magnetic resonance imaging examinations were per-
formed to evaluate RV function and TR severity
following the procedure due to the lack of data on de-
vice magnetic resonance compatibility. Finally, there
was no systematic evaluation of BNP levels.
CONCLUSIONS
Transcatheter reduction of secondary tricuspid valve
regurgitation appears safe and feasible with this
transcatheter repair system. TR reduction was
observed in all patients, along with improvements in
peripheral edema and functional status. Longer-term
follow-up and larger studies are required to conﬁrm
these preliminary results.
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